Please login to the form below

Not currently logged in
Email:
Password:

aripiprazole

This page shows the latest aripiprazole news and features for those working in and with pharma, biotech and healthcare.

Indivior push to diversify boosted by schizophrenia drug approval

Indivior push to diversify boosted by schizophrenia drug approval

It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson &Johnson’s Invega Sustenna (paliperidone) but, for now, Indivior

Latest news

  • First digital medicine approved in the US First digital medicine approved in the US

    Abilify MyCite is the latest iteration of antipsychotic blockbuster Abilify (aripiprazole) to reach the market, and is approved for the same indications as its parent products - schizophrenia, bipolar I disorder and ... The product takes the form of an

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    It has a long way to go however before it can reach the heights of its predecessor - Abilify (aripiprazole) - which was a mainstay for both Lundbeck and Otsuka but has fallen

  • Otsuka refiles 'digital' medicine for mental illness Otsuka refiles 'digital' medicine for mental illness

    The so-called 'digital medicine' consists of Otsuka's Abilify (aripiprazole) embedded with Proteus' ingestible sensor that is the size of a grain of sand, which records medication ingestion.

  • Surging sales of Lundbeck's CNS drugs assist recovery Surging sales of Lundbeck's CNS drugs assist recovery

    Schizophrenia depot Abilify Maintena (aripiprazole) was up 78% to DKK 279m, and new drug for high blood pressure associated with Parkinson's disease - Northera (droxidopa) - romped away with a 136% rise

  • FDA knocks-back Otsuka's digital pill plans FDA knocks-back Otsuka's digital pill plans

    Otsuka had submitted the device for approval to measure medication adherence to Abilify (aripiprazole) in patients with schizophrenia, as an acute treatment of manic and mixed episodes associated with bipolar I

More from news
Approximately 6 fully matching, plus 55 partially matching documents found.

Latest Intelligence

  • Tools for the digital world Tools for the digital world

    In May Proteus and Otsuka Pharmaceutical Co resubmitted a New Drug Application for the drug-device combination product of Ablify (aripiprazole) embedded with a Proteus ingestible sensor in a single tablet.

  • Pharma deals during March 2013 Pharma deals during March 2013

    At the end of February, the FDA approved Abilify Maintena (aripiprazole), an intramuscular extended-release depot formulation for the treatment of schizophrenia and the first commercialised product to evolve from this

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics